ArticleScientific reports2025
Exploration of effective biomarkers and infiltrating immune cells in metastatic colorectal cancer based on bioinformatics analysis.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Thalidomide-mediated immunomodulation in a patient withFrontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Colorectal cancer (CRC) ranks as the third most prevalent malignancy globally and represents the second leading cause of cancer-related mortality worldwide. Metastatic colorectal cancer (mCRC) is clinically classified as an advanced-stage malignancy, characterized by therapeutic resistance and substantially diminished survival outcomes. The 5-year survival rate for mCRC is significantly lower than that for early-stage CRC. A multi-dimensional computational framework was implemented to dissect CRC transcriptomics. Gene expression profiles were systematically acquired from TCGA and GEO repositories. A series of data were then analyzed using ssGSEA algorithm, xCell algorithm, edgeR, limma, DAVID enrichment analysis, CytoHubba, ROC logistic regression and correlation analysis. Immune cell infiltration analysis revealed 7 tumor-infiltrating immune cell subtypes exhibiting significant abundance disparities between metastatic and non-metastatic colorectal cancer cohorts. Further integrative analysis identified 28 immune-related metastatic colorectal cancer differentially expressed genes (ICDEGs) in metastatic lesions. Through comprehensive analysis, 9 pivotal hub genes (AGTR1, CD86, CMKLR1, FGF1, FYN, IL10RA, INHBA, TNFSF13B, and VEGFC) were successfully identified. Notably, AGTR1, CD86, CMKLR1 and TNFSF13B genes have been rarely reported in mCRC. Furthermore, our correlation studies revealed significant inverse relationships between epithelial cells and three specific genes: TNFSF13B, CD86, and IL10RA. The identified 9 hub genes demonstrate significant potential as reliable diagnostic biomarkers for mCRC. Moreover, these molecular markers may contribute to disease pathogenesis through their dynamic interactions with tumor-infiltrating immune cells, suggesting a crucial role in the tumor microenvironment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.